VeraABittnerMD
Cardiology • Birmingham, ALNuclear Cardiology, Preventive Cardiology, Exercise Physiology and Cardiac Rehabilitation, Cardiac Critical Care
Professor, Medicine, University of Alabama School of Medicine
Dr. Bittner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2000 6th Ave S
Birmingham, AL 35233Phone+1 205-934-9999
Summary
- Section Head, Preventive Cardiology
Education & Training
University of Alabama Medical CenterFellowship, Cardiovascular Disease, 1984 - 1987
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 1981 - 1984
University of South Alabama College of MedicineClass of 1981
Certifications & Licensure
AL State Medical License 1984 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- 1235 citationsExercise Standards for Testing and Training A Scientific Statement From the American Heart AssociationGerald F. Fletcher, Philip A. Ades, Paul Kligfield, Ross Arena, Gary J. Balady
Circulation. 2013-08-20 - 18 citationsHybrid cardiac rehabilitation - The state of the science and the way forward.Brittain Heindl, Luke Ramirez, Luke Joseph, Stephen Clarkson, Randal Thomas
Progress in Cardiovascular Diseases. 2021-12-24 - 416 citationsReferral, Enrollment, and Delivery of Cardiac Rehabilitation/Secondary Prevention Programs at Clinical Centers and Beyond A Presidential Advisory From the American Hea...Gary J. Balady, Philip A. Ades, Vera Bittner, Barry A. Franklin, Neil F. Gordon
Circulation. 2011-12-20
Journal Articles
- Original Investigations Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES TrialGregory G Schwartz, Vera A Bittner, ScienceDirect
- Alirocumab and Cardiovascular Outcomes After Acute Coronary SyndromeVera A Bittner, Kenneth W Mahaffey, Deepak L Bhatt, Robert A Harrington, Gregory G Schwartz, Matthew T Roe, The New England Journal of Medicine
- Do Not Smoke, Eat Healthy, and ExerciseVera Bittner, MD, JACC: Cardiovascular Imaging
Lectures
- Lipoprotein(a) Lowering by Alirocumab Contributes to Total Events Reduction Independent of Low-Density Lipoprotein Cholesterol in the ODYSSEY OUTCOMES Trial2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Late-Breaking Clinical Trials2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Hypertension Management Hypercharged: The Devil is in the Details2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
- Join now to see all
Authored Content
- Do Not Smoke, Eat Healthy, and ExerciseNovember 2018
- Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United StatesApril 2018
- Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United StatesApril 2018
Press Mentions
Cholesterol Medications, Flu Shots and Heart Failure: Day 2 at ACC.22April 4th, 2022- APOLLO: SLN360 Clears First Major Hurdle, Hammering Lp(A)April 3rd, 2022
- New Analysis Finds Broader Benefit for Post ACS Ezetimibe-Statin ComboOctober 5th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
